Search results
Nov 16, 2023 · 2:48. US Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator that were marked by controversy over support for unproven ...
Jan 20, 2021 · By Beth Snyder Bulik Jan 20, 2021 5:32pm. Janet Woodcock, M.D., is the FDA's new acting commissioner, stepping into the role on President Joe Biden's inauguration day. (FDA ) Just hours after U.S ...
Jan 28, 2022 · Acting FDA Commissioner Janet Woodcock spoke with STAT about what comes next for the regulation of Covid drugs and vaccines. This interview has been edited for clarity. advertisement.
After a 35-year career, Janet Woodcock is expected to wind down her time at the US Food and Drug Administration in 2022 having never held the agency’s most senior role – commissioner – permanently. But that hasn’t stopped her from being one of the most powerful forces in modern drug regulation, and in fact may have been what kept her so ...
Feb 3, 2021 · Janet Woodcock — often referred to as “the top drug cop” — had been in charge of CEDR for only a year in 1995 when the FDA considered approving OxyContin for sale to the public. Purdue ...
Nov 30, 2023 · For almost 40 years, Janet Woodcock has provided leadership across the entire spectrum of FDA regulation. Her retirement was inevitable — there has been speculation every year for the past decade — but now it’s real. It has been officially announced that she will retire from federal service in early 2024.
Feb 7, 2024 · Under Dr. Woodcock’s guidance, hundreds of highly productive collaborations have been initiated, significantly accelerating the safe development of new drugs and biomedical products. “I had the pleasure of working with Janet to launch the highly successful Critical Path Institute,” said C-Path founder Dr. Ray Woosley.
